• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CDK1 和 BUB1 的高表达预示着胰腺导管腺癌预后不良。

High expression of CDK1 and BUB1 predicts poor prognosis of pancreatic ductal adenocarcinoma.

机构信息

Department of Pathology and Cancer Research Center, Yanbian University Medical College, Yanji 133002, China; Key Laboratory of the Science and Technology Department of Jilin Province, Yanji 133002, China.

Department of Dermatology, Yanbian University Hospital, Yanji 133000, China.

出版信息

Gene. 2019 Jun 15;701:15-22. doi: 10.1016/j.gene.2019.02.081. Epub 2019 Mar 18.

DOI:10.1016/j.gene.2019.02.081
PMID:30898709
Abstract

BACKGROUND

Pancreatic ductal adenocarcinoma (PDAC) is one of the most common causes of cancer-related death. Increasing evidence suggests that cell cycle dysregulation is one of the hallmarks of cancer. In this study, by using the GEO database, we predicted the cell cycle-related protein CDK1 and BUB1 to be significantly overexpressed in PDAC tissues. Thus, this study aimed to investigate the clinical pathological significance of CDK1 and BUB1 in PDAC.

METHODS

To explore the role of CDK1 and BUB1 in PDAC progression and evaluate their prognostic value, we investigated the expression patterns of CDK1 and BUB1 by using immunohistochemical staining in 99 PDAC and 71 normal pancreatic tissues with complete pathological parameters and survival data.

RESULTS

CDK1 and BUB1 were significantly overexpressed in PDAC tissues. The expression of CDK1 was correlated with tumor size and histological grade, and the expression of BUB1 was correlated with the tumor size of PDAC. With regard to survival, a high expression of either CDK1 or BUB1 was correlated with a short survival of PDAC patients. Additionally, PDAC patients with a concurrent high expression of CDK1 and BUB1 showed the shortest survival.

CONCLUSIONS

Our study demonstrated that CDK1 and BUB1 may play a role in PDAC progression and could be prognostic biomarkers for PDAC patients.

摘要

背景

胰腺导管腺癌(PDAC)是癌症相关死亡的最常见原因之一。越来越多的证据表明,细胞周期失调是癌症的标志之一。在这项研究中,我们通过使用 GEO 数据库,预测细胞周期相关蛋白 CDK1 和 BUB1 在 PDAC 组织中显著过表达。因此,本研究旨在探讨 CDK1 和 BUB1 在 PDAC 中的临床病理意义。

方法

为了探讨 CDK1 和 BUB1 在 PDAC 进展中的作用并评估其预后价值,我们使用免疫组织化学染色法检测了 99 例 PDAC 组织和 71 例具有完整病理参数和生存数据的正常胰腺组织中 CDK1 和 BUB1 的表达模式。

结果

CDK1 和 BUB1 在 PDAC 组织中显著过表达。CDK1 的表达与肿瘤大小和组织学分级相关,而 BUB1 的表达与 PDAC 的肿瘤大小相关。就生存而言,CDK1 或 BUB1 的高表达与 PDAC 患者的短生存期相关。此外,同时高表达 CDK1 和 BUB1 的 PDAC 患者的生存期最短。

结论

我们的研究表明,CDK1 和 BUB1 可能在 PDAC 进展中发挥作用,并可能成为 PDAC 患者的预后生物标志物。

相似文献

1
High expression of CDK1 and BUB1 predicts poor prognosis of pancreatic ductal adenocarcinoma.CDK1 和 BUB1 的高表达预示着胰腺导管腺癌预后不良。
Gene. 2019 Jun 15;701:15-22. doi: 10.1016/j.gene.2019.02.081. Epub 2019 Mar 18.
2
Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues predicts poor survival in pancreatic ductal adenocarcinoma.肿瘤组织中 BUB1B、CCNA2、CDC20 和 CDK1 的过表达预示着胰腺导管腺癌患者的预后不良。
Biosci Rep. 2019 Feb 26;39(2). doi: 10.1042/BSR20182306. Print 2019 Feb 28.
3
Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.Linc00675是胰腺导管腺癌患者短期生存和复发的一种新型标志物。
World J Gastroenterol. 2015 Aug 21;21(31):9348-57. doi: 10.3748/wjg.v21.i31.9348.
4
Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.埃兹蛋白过表达预示胰腺导管腺癌预后不良。
Exp Mol Pathol. 2015 Feb;98(1):1-6. doi: 10.1016/j.yexmp.2014.11.003. Epub 2014 Nov 5.
5
The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.FRAT1和ABCG2在胰腺导管腺癌中的表达的临床意义。
Tumour Biol. 2015 Dec;36(12):9961-8. doi: 10.1007/s13277-015-3752-0. Epub 2015 Jul 16.
6
DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.DEK蛋白过表达预示胰腺导管腺癌预后不良。
Oncol Rep. 2017 Feb;37(2):857-864. doi: 10.3892/or.2016.5302. Epub 2016 Dec 8.
7
Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.Sineoculis homeobox homolog 1 蛋白过表达可作为胰腺导管腺癌的独立生物标志物。
Exp Mol Pathol. 2014 Feb;96(1):54-60. doi: 10.1016/j.yexmp.2013.11.003. Epub 2013 Nov 18.
8
Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer.MAP4K5在胰腺癌中的预后及功能意义
PLoS One. 2016 Mar 29;11(3):e0152300. doi: 10.1371/journal.pone.0152300. eCollection 2016.
9
High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC).表皮生长因子受体3结合蛋白1(EBP1)的高表达预示着胰腺导管腺癌(PDAC)的预后不良。
Tumour Biol. 2015 Dec;36(12):9189-99. doi: 10.1007/s13277-015-3625-6. Epub 2015 Jun 19.
10
BIRC7 and KLF4 expression in benign and malignant lesions of pancreas and their clinicopathological significance.BIRC7和KLF4在胰腺良恶性病变中的表达及其临床病理意义。
Cancer Biomark. 2016;17(4):437-444. doi: 10.3233/CBM-160660.

引用本文的文献

1
Genome-wide CRISPR screen identifies BUB1 kinase as a druggable vulnerability in malignant pleural mesothelioma.全基因组CRISPR筛选确定BUB1激酶是恶性胸膜间皮瘤中的一个可药物靶向的脆弱靶点。
Cell Death Dis. 2025 Apr 3;16(1):241. doi: 10.1038/s41419-025-07587-z.
2
BUB1 serves as a biomarker for poor prognosis in liver hepatocellular carcinoma.BUB1作为肝细胞癌预后不良的生物标志物。
BMC Immunol. 2025 Mar 11;26(1):20. doi: 10.1186/s12865-025-00698-4.
3
BUB1 as a novel marker for predicting the immunotherapy efficacy and prognosis of breast cancer.
BUB1作为预测乳腺癌免疫治疗疗效和预后的新型标志物。
Transl Cancer Res. 2024 Sep 30;13(9):4534-4554. doi: 10.21037/tcr-24-704. Epub 2024 Sep 27.
4
Mechanisms of Berberine in anti-pancreatic ductal adenocarcinoma revealed by integrated multi-omics profiling.基于整合多组学分析揭示小檗碱抗胰腺导管腺癌的作用机制。
Sci Rep. 2024 Oct 2;14(1):22929. doi: 10.1038/s41598-024-74943-y.
5
Discovery of Potential Inhibitors of CDK1 by Integrating Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation Studies, and Evaluation of Their Inhibitory Activity.通过整合基于药效团的虚拟筛选、分子对接、分子动力学模拟研究及其抑制活性评估发现细胞周期蛋白依赖性激酶1(CDK1)的潜在抑制剂
ACS Omega. 2024 Sep 13;9(38):39873-39892. doi: 10.1021/acsomega.4c05414. eCollection 2024 Sep 24.
6
Stage analysis of pancreatic ductal adenocarcinoma via network analysis.通过网络分析对胰腺导管腺癌进行阶段分析。
Gastroenterol Hepatol Bed Bench. 2024;17(3):297-3030. doi: 10.22037/ghfbb.v17i3.2887.
7
CDK1 Acts as a Prognostic Biomarker Associated with Immune Infiltration in Pan-Cancer, Especially in Gastrointestinal Tumors.细胞周期蛋白依赖性激酶1作为一种与泛癌尤其是胃肠道肿瘤免疫浸润相关的预后生物标志物。
Curr Med Chem. 2024 Jun 28. doi: 10.2174/0109298673322212240620111356.
8
SRSF9 promotes cell proliferation and migration of glioblastoma through enhancing CDK1 expression.SRSF9 通过增强 CDK1 的表达促进脑胶质母细胞瘤的增殖和迁移。
J Cancer Res Clin Oncol. 2024 Jun 6;150(6):292. doi: 10.1007/s00432-024-05797-0.
9
Unraveling malignant phenotype of peritumoral tissue: transcriptomic insights into early-stage breast cancer.解析肿瘤周围组织的恶性表型:早期乳腺癌的转录组学研究。
Breast Cancer Res. 2024 Jun 3;26(1):89. doi: 10.1186/s13058-024-01837-2.
10
BUB1 Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Inhibiting Ferroptosis.BUB1通过抑制铁死亡促进胰腺癌细胞对吉西他滨的耐药性。
Cancers (Basel). 2024 Apr 18;16(8):1540. doi: 10.3390/cancers16081540.